Aytu BioScience announces European distribution for MiOXSYS infertility drug

Aytu BioScience announces European distribution for MiOXSYS infertility drug

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced it has entered... Read More

Tuesday June 14, 2016 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, MiOXSYS

Aytu BioScience study demonstrates expanded utility of MiOXSYS for assessing oxidative stress as male infertility marker

Aytu BioScience study demonstrates expanded utility of MiOXSYS for assessing oxidative stress as male infertility marker

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced new clinical... Read More

Tuesday May 10, 2016 0 comments Tags: Englewood, Aytu BioScience, Ashok Agarwal, Josh Disbrow, MiOXSYS

Aytu Bioscience acquires rights to Natesto drug

Aytu Bioscience acquires rights to Natesto drug

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced the exclusive licensing... Read More

Monday April 25, 2016 0 comments Tags: Aytu BioScience, Englewood, Natesto, Acerus Pharma, Josh Disbrow, Tom Rossi

Aytu BioScience awarded Health Canada approval for its MiOXSYS™ system for male infertility

Aytu BioScience awarded Health Canada approval for its MiOXSYS™ system for male infertility

ENGLEWOOD -- Aytu BioScience, Inc . (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on global commercialization of novel products in the field of urology, announced it has... Read More

Wednesday April 6, 2016 0 comments Tags: Englewood, Josh Disbrow, Aytu BioScience, MiOXSYS

Aytu BioScience announces U.S. co-promotion agreement for Primsol

Aytu BioScience announces U.S. co-promotion agreement for Primsol

ENGLEWOOD -- Aytu BioScience , Inc.(OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced the company... Read More

Tuesday March 29, 2016 0 comments Tags: Englewood, Aytu BioScience, Primsol, Josh Disbrow, Allegis Pharmaceuticals

Aytu Bioscience announces first sales for male infertility system

Aytu Bioscience announces first sales for male infertility system

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced the first... Read More

Tuesday February 9, 2016 0 comments Tags: Aytu BioScience, Josh Disbrow, Englewood, MiOXSYS, male infertility

Aytu adds two founders to board of directors

Aytu adds two founders to board of directors

ENGLEWOOD -- Aytu BioScience, Inc .(OTCQX: AYTU), a specialty healthcare company focused on commercializing treatments for urological and related conditions, announced Josh Disbrow , Aytu''s... Read More

Thursday January 28, 2016 0 comments Tags: Aytu BioScience, Josh Disbrow, Jarrett Disbrow, Englewood, Michael Macaluso, MiOXSYS

Aytu appoints Jonathan Heath McGrael VP of sales

Aytu appoints Jonathan Heath McGrael VP of sales

ENGLEWOOD-- Aytu BioScience Inc . (OTCQB: AYTU), a specialty health care company developing treatments for urological and related conditions, announced the appointment of Jonathan Heath McGrael ... Read More

Thursday September 10, 2015 0 comments Tags: Englewood, Aytu BioScience, Jonathan Heath McGra, Josh Disbrow, ProstaScint